ANTI-CD20 MONOCLONAL ANTIBODIES IN TREATMENT OF HAEMOLYTIC ANEMIA IN A TEENAGE GIRL WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.15690/vsp.v11i6.508
Abstract
Haemolytic anemia occurs in 10% of the cases of systemic lupus erythematosus in children with hematological disturbances. High doses of glucocorticoids are used for the treatment of this condition. The second-line drugs in cases of refractory disease course are azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide. Rituximab (anti-CD20 monoclonal antibodies) is used for treatment of systemic lupus erythematosus, resistant to the standard immunosuppressive therapy. In this article a history case of successful treatment of haemolytic anemia in a teenage girl with systemic lupus erythematosus is demonstrated. Rituximab treatment allowed to avoid the increasing of glucocorticoids dose and cyclophosphamide introduction, as well as to prevent severe side-effects of afore-mentioned drugs. However in order to establish the duration of the clinical effect, safety of performed treatment and adjustment of appropriate drug dosage the data of multicenter randomized controlled trials are needed.
About the Authors
R. V. Denisova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Petty R. E., Laxer R. M. Systemic lupus erythematosus. In: J. T. Cassidy, R. E. Petty, R. M. Laxer, C. B. Lindsley (eds.). Textbook of pediatric rheumatology. Philadelphia, PA: Elsevier Saunders. 2005. P. 342–391.
2. Tucker L. B., Menon S., Scharler J. G., Isenberg D. A. Adult and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. Br. J. Rheumatol. 1995; 34: 866–872.
3. Carreno L., Lopez-Longo F. J., Monteagudo I. Rodriguez- Mahou M., Bascones M., Gonzalez C. M., Saint-Cyr C., Lapointe N. Immunological and clinical differences between juvenile and adult onset of systemic lupus erytematosus. Lupus. 1999; 8: 287–292.
4. Costallat L. T., Coimbra A. M. Systemic lupus erythematosis; clinical and laboratory aspects related to age at disease onset. Clin. Exp. Rheumatol. 1994; 12: 603–607.
5. Cervera R., Kamashtha M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Domenech I., Aydintug A. O., Jedryka-Goral A., de Ramon E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine. 1993; 72: 113–124.
6. Pugh-Bernard A. E., Cambier J. C. B cell receptor signaling in human systemic lupus erythematosus. Curr. Opin. Rheumatol. 2006; 18: 451–455.
7. Mohan C., Datta S. K. Lupus: key pathogenic mechanisms and contributing factors. Clin. Immunol. Immunopathol. 1995; 77: 209–220.
8. Prodeus A. P., Goerg S., Shen L. M., Pozdnyakova O. O., Chu L., Alicot E. M., Goodnow C. C., Carroll M. C. A critical role for complement in maintenance of self-tolerance. Immunity. 1998; 9: 721–731.
9. Yurasov S., Wardemann H., Hammersen J. Tsuiji M., Meffre E., Pascual V., Nussenzweig M.C. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 2005; 20: 703–711.
10. Shan D., Ledbetter J. A., Press O. W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother 2000; 48: 673–683.
11. Flieger D., Renoth S., Beier I., Sauerbruch T., Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC–C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000; 204: 55–63.
12. Alas S., Emmanouilides C., Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of Bcell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res. 2001; 7: 709–723.
13. Anolik J. H., Campbell D., Felgar R. E. Young F., Sanz I., Rosenblatt J., Looney R.J. The relationship of Fc_RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 455–459.
14. Boye J., Elter T., Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 2003; 14: 520–535.
15. El-Hallak M., Binstadt B. A., Leichtner A. M. Bennett C.M., Neufeld E.J., Fuhlbrigge R.C., Zurakowski D., Sundel R.P. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J. Pediatr. 2007; 150: 376–382.
16. Giulino L. B., Brussel J. B., Neufeld E. J. Pediatric and Platelet Immmunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J. Pediatr. 2007; 150: 338–344.
17. Bensler S. M., Silverman E. D. Systemic lupus erythematosus. Pediatr. Clin. North Am. 2005; 5: 443–467. 18. Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus. 2003; 12: 798–800.
18. Kotani T., Takeuchi T., Kawasaki Y. Hirano S., Tabushi Y., Kagitani M., Makino S., Hanafusa T. Successful treatment of cold agglutin disease with anti CD20 antibody (rituximab) in patient with systemic lupus erythematosus. Lupus. 2006; 15: 683–685.
19. Gomard-Mennesson E., Ruivard M., Koenig M., Woods A., Magy N., Ninet J., Rousset H., Salles G., Broussolle C., Sуve P. Treatment of islolated severe immune hemolytic anemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006; 15: 223–231.
20. Perrotta S., Locatelli F., La Manna A., Cennamo L., De Stefano P., Nobili B. Anti-CD20 monoclonal antibody (rituximab) for lifethreatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br. J. Haematol. 2002; 116: 465–467.
21. Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., Jankovic M., Pierani P., De Stefano P., Bonora M. R., Locatelli F. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003; 101: 3857–3861.
22. Willems M., Haddad E., Niaudet P., Kone-Paut I., Bensman A., Cochat P., Deschenes G., Fakhouri F., Leblanc T., Llanas B., Loirat C., Pillet P., Ranchin B., Salomon R., Ulinski T., Bader-Meunier B. French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr. 2006; 148: 623–627.
23. Abdwani R., Mani R. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE. Lupus. 2009; 18: 460–464.
24. Laxer R. M. Pharmacology and drug therapy. In: J. T. Cassidy, R. E. Petty, R. M. Laxer, C. B. Lindsley (eds.). Textbook of pediatric rheumatology. Philadelphia, PA: Elsevier Saunders. 2005. P. 76–141.
25. Byrd J. C., Murphy T., Howard R. S., Lucas M. S., Goodrich A., Park K., Pearson M., Waselenko J. K., Ling G., Grever M. R., Grillo- Lopez A. J., Rosenberg J., Kunkel L., Flinn I. W. Rituximab using a thriceweekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 2001; 19: 2153–2164.
26. Package insert: Rituxan (rituximab). San Diego, CA: IDEC Pharmaceuticals Corp. 2003.
27. Алексеева Е. И., Валиева С. И., Бзарова Т. М. Семикина Е. Л., Исаева К. Б., Лисицын А. О., Денисова Р. В., Гудкова Е. Ю. Эффек- тивность и безопасность повторных курсов лечения ритуксима- бом тяжелого рефрактерного ювенильного артрита. Вопр. совр. педиатрии. 2009; 8 (5): 19–30.
28. Alexeeva E.I., Valieva S.I., Bzarova T.M., Semikina E.L., Isaeva K.B., Lisitsyn A.O., Denisova R.V., Chistyakova E.G. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30 (9): 1163–1172.
29. MacDermott E. J., Lehman T. J. Prospective, open-label trial of rituximab in childhood systemic lupus erythematosus. Curr. Rheumatol. Rep. 2006; 8: 439–441.
30. Marks S. D., Patey S., Borgan P. A., Hasson N., Pilkington C., Woo P., Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythmatosus. Arthritis Rheum. 2005; 52: 3168–3173.
31. Poldolskaya A., Stdermann M., Pilikington C., Mark S. D., Tullus K. Bcell depletion therapy for 19 patients with refractory lupus erythematosus. Arch. Dis. Child. 2008; 93: 401–406.
32. Nwobi O., Abitbol C. L., Chandar J., Seeherunvong W., Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr. Nephrol. 2008; 23: 413–419 (abstract).
Review
For citations:
Denisova R.V., Alexeeva E.I. ANTI-CD20 MONOCLONAL ANTIBODIES IN TREATMENT OF HAEMOLYTIC ANEMIA IN A TEENAGE GIRL WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Current Pediatrics. 2012;11(6):147-152. (In Russ.) https://doi.org/10.15690/vsp.v11i6.508
Views:
2292
Email this article 
